We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
BioTelemetry (BEAT - Free Report) closed the most recent trading day at $72.34, moving +0.72% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.09%. Elsewhere, the Dow gained 0.26%, while the tech-heavy Nasdaq lost 0.25%.
Prior to today's trading, shares of the heart monitoring device maker had gained 29.76% over the past month. This has outpaced the Medical sector's gain of 5.59% and the S&P 500's gain of 7.92% in that time.
BEAT will be looking to display strength as it nears its next earnings release, which is expected to be February 28, 2019. The company is expected to report EPS of $0.42, up 31.25% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $103.02 million, up 12.29% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for BEAT. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BEAT is currently a Zacks Rank #2 (Buy).
Looking at its valuation, BEAT is holding a Forward P/E ratio of 40.35. Its industry sports an average Forward P/E of 20.55, so we one might conclude that BEAT is trading at a premium comparatively.
Investors should also note that BEAT has a PEG ratio of 4.03 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services was holding an average PEG ratio of 1.62 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioTelemetry (BEAT) Outpaces Stock Market Gains: What You Should Know
BioTelemetry (BEAT - Free Report) closed the most recent trading day at $72.34, moving +0.72% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.09%. Elsewhere, the Dow gained 0.26%, while the tech-heavy Nasdaq lost 0.25%.
Prior to today's trading, shares of the heart monitoring device maker had gained 29.76% over the past month. This has outpaced the Medical sector's gain of 5.59% and the S&P 500's gain of 7.92% in that time.
BEAT will be looking to display strength as it nears its next earnings release, which is expected to be February 28, 2019. The company is expected to report EPS of $0.42, up 31.25% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $103.02 million, up 12.29% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for BEAT. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. BEAT is currently a Zacks Rank #2 (Buy).
Looking at its valuation, BEAT is holding a Forward P/E ratio of 40.35. Its industry sports an average Forward P/E of 20.55, so we one might conclude that BEAT is trading at a premium comparatively.
Investors should also note that BEAT has a PEG ratio of 4.03 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical Services was holding an average PEG ratio of 1.62 at yesterday's closing price.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.